ArticlemedRxiv : the preprint server for health sciences2025
Health, Equity, and Economic Impacts of a Nicotine Product Standard in the United States for People With and Without Major Depression.
Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Importance: The U.S. FDA has proposed a product standard that would reduce the nicotine content and addictiveness of cigarettes. It is unclear what impact this would have on economic outcomes or priority populations who are disproportionately harmed by tobacco use, such as people with major depression. Objective: To evaluate the long-term health and economic impacts of a nicotine product standard for the U.S. population by depression status. Design Setting and Participants: A microsimulation model was developed and calibrated to National Survey on Drug Use and Health (NSDUH) 2005-2023 data on smoking, vaping, and depressive episodes. The anticipated effects of the nicotine product standard on smoking and vaping were obtained from an FDA expert elicitation and used to simulate the policy from 2027-2100. Exposure: Smoking and vaping. Main Outcomes and Measures: Health outcomes included prevalence of smoking and vaping, deaths, and life years gained overall and by major depression status. Economic outcomes include direct costs to the healthcare system and societal costs. Results: Under the proposed nicotine product standard, smoking is projected to decline to <1% for people with and without depression by 2100. The policy is estimated to avert 1.7 million premature deaths and lead to 74.7 million life years gained. Depression prevalence is also expected to decline, with 8.5 million fewer cases of depression estimated. Longer life expectancies under the policy are projected to increase medical costs by $296 billion, while also increasing worker productivity by $266 billion with an additional $1.2 trillion in consumer spending. Conclusions and Relevance: Timely implementation of a nicotine reduction strategy, either through a federal product standard or state-level sales restrictions, is cost-effective and could prevent millions of premature deaths and reduce smoking disparities by depression status.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.